Carlyle / SK Capital Partners to acquire bluebird bio

CARLYLE, SK Capital Partners and Bluebird have agreed to acquire a private company in a private equity acquisition announced on 6 April 2025. The transaction involves a consortium of three distinct investment firms acting jointly as the acquiring party. No specific target name or sector classification was confirmed in the available data, and the deal value remains undisclosed. The consideration structure has not been reported, leaving the precise financial terms of the arrangement unknown to the public.

The acquisition is currently in the review phase with regulatory authorities. The parties have not yet confirmed a completion date for the transaction. Further details regarding the specific industry or the strategic direction of the combined entity are not available at this time. The deal status remains pending final approvals before the transaction can be formally concluded.